CRT + sintilimab

CRT + sintilimab is a combination therapy that pairs chemoradiotherapy (CRT) with sintilimab, an immune checkpoint inhibitor. This combination has shown promising results in several cancer types, particularly in esophageal squamous cell carcinoma (ESCC)[4]. The therapy works by combining the cytotoxic effects of chemotherapy and radiation with the immunotherapeutic properties of sintilimab. Sintilimab is a PD-1 inhibitor that helps the immune system recognize and attack cancer cells by blocking the interaction between PD-1 and PD-L1[1][3]. When combined with traditional chemoradiotherapy, this approach appears to enhance treatment efficacy. ## Clinical Evidence Recent clinical trials have demonstrated significant benefits of this combination therapy: - In the phase 3 SCIENCE trial (NCT05244798), sintilimab plus neoadjuvant chemoradiotherapy achieved a pathological complete response (pCR) rate of 60% compared to 47.3% with CRT alone in patients with resectable, locally advanced esophageal squamous cell carcinoma[4]. - The combination was significantly superior to sintilimab plus chemotherapy without radiation, which only achieved a 13% pCR rate[4]. - According to Dr. Xuefeng Leng of Sichuan Cancer Hospital, "Adding sintilimab to neoadjuvant CRT may improve the pathological outcomes without increasing surgical risks," suggesting this combination "has the potential to become the new standard of care in the near future"[4]. - Another study showed that concurrent sintilimab with sequential chemoradiotherapy (SCRT) resulted in significantly better objective response rates and longer progression-free survival than SCRT alone in patients, with manageable safety profiles[6]. ## Other Applications The combination approach of immunotherapy with conventional treatments appears effective in multiple cancer types: - In gastric or gastroesophageal junction adenocarcinoma, adding sintilimab to standard chemotherapy significantly improved overall survival and progression-free survival compared with placebo plus standard chemotherapy[3]. - For patients with a Combined Positive Score (CPS) of 5 or more, the objective response rate was 63.6% in the sintilimab group versus 49.4% in the placebo group[3]. - A case report of a 67-year-old man with primary pulmonary choriocarcinoma showed significant tumor reduction after treatment with a combination of cisplatin, etoposide, paclitaxel, and sintilimab[1]. The emerging data suggests that CRT + sintilimab represents a promising therapeutic approach that may become a new standard of care for certain cancer types, particularly resectable, locally advanced esophageal squamous cell carcinoma.

Other names

sintilimab plus chemoradiotherapysintilimab with chemoradiotherapyneoadjuvant CRT + sintilimabconcurrent SCRT + sintilimab